Development Technology Sample Clauses

Development Technology. All right, title and interest in and to the Development Technology shall, as between the Parties, be owned solely by Millennium. Sunesis hereby assigns to Millennium all of Sunesis’s and its Affiliates’ rights in and to the Development Technology (including all patent and other intellectual property rights therein), subject to the licenses granted to Sunesis under Article 5.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Development Technology. All right, title and interest in and to the Development Technology and the DOT-1 Collaboration Technology shall, as between the Parties, be owned solely by DOT-1.
Sample 1Sample 2
Development Technology. With respect to the rights of Trimeris to develop a Development Compound or Product, Trimeris shall have the right to engage a Third Party contractor in formulation technology or delivery technology or product criteria maximization to the extent Trimeris deems necessary for achieving a Product it desires to commercialize. A written agreement of Trimeris with such Third Party subcontractor shall have provisions regarding confidentiality and prohibitions on transfer of information, and non-use and ownership of intellectual property, consistent with those contained herein. If, during the Third Party subcontracting a new invention not covered by Collaboration Technology is conceived and/or reduced to practice (“Development Technology”) relating to the formulated or deliverable Product (“Modified Product”), Trimeris shall use its best efforts to negotiate sole ownership of Modified Product, or at least joint ownership with the Third Party contractor. In such event, the Parties shall negotiate in good faith to successfully complete negotiation of the operative and financial terms between the Parties for such commercialization of a Modified Product, such operative and financial terms shall in no instance exceed payment terms provided for such Product according to Article 6. If the Parties fail to successfully complete such negotiation within a reasonable time period, the Parties agree that the operative and financial terms for such commercialization shall be determined and settled by binding arbitration in an arbitration process set forth in Article 14 herein.
Sample 1Sample 2
Development Technology. 1. Each party will promptly disclose to the other in writing all ideas invented, discovered or developed by such party relating in any manner to the Development Technology. PEC will have sole ownership of and the sole right to file, prosecute, and maintain all of the patents covering the inventions relating to the X-Ray Tube and the Control Device, including all improvements thereto, whether patentable or not and whether invented, discovered or developed by PEC, Cordis, or jointly by PEC and Cordis, or their respective employees or agents. Cordis will have sole ownership of and the sole right to file, prosecute, and maintain all the patents covering the inventions relating to the Catheter Body Subassembly and the Delivery Device, including all improvements thereto, whether patentable or not and whether invented, discovered, or developed by PEC, Cordis or jointly by PEC and Cordis, or their respective employees or agents. Each party will assign, and will require its employees and agents to assign to the party owning the same, all rights, title and interest to any such inventions, discoveries or developments. PEC and Cordis will jointly own any inventions, discoveries or developments related to the X-Ray System, including all improvements and/or modifications thereto, whether patentable or not and whether invented, discovered or developed by PEC, Cordis, or jointly by PEC and Cordis, or their respective employees or agents. After the dissolution of the Steering Committee, Cordis will have the sole right to file, prosecute, and maintain all of the patents related to improvements and/or modifications to the X-Ray System that are jointly owned, and will have the right to determine whether or not, and when, to file a patent application, to abandon the prosecution of any patent or patent application, or to discontinue the maintenance of any patent or patent application with respect to such improvements and/or modifications. PEC and Cordis will share equally in the costs/fees associated with the preparation, filing, prosecution and maintenance of jointly owned patents on a country by country basis. For any country in which PEC chooses not to participate, sole ownership of the patent application and the resulting patent in such country will reside in Cordis.
Sample 1
Development Technology. Subject to BASF's rights herein and in the Exclusivity MOU, as between the Parties Nanophase shall have the entire and exclusive worldwide rights, title, and interest in and to all technology developments created by the Parties in their work on the [*] project set forth herein, relating to: (i) methods of manufacturing [**] zinc oxide powder; (ii) use and sale of [**] zinc oxide powder or dispersions for Finished Goods and Custom Dispersions (each as defined in the Exclusivity MOU) in the Field; and (iii) use and sale of [**] zinc oxide powder and dispersions other than for uses in the Field. Nanophase, in its sole discretion and expense, shall have the right to prepare, file, prosecute, maintain, and enforce patents and patent applications directed to (i), (ii), or (iii) above.
Sample 1
Development Technology. Miravant shall own the entire right, title and interest in all Development Technology, whether conceived solely by its employees or consultants or conceived solely by or jointly with employees or consultants of P&U or its Affiliates and employees or consultants. P&U hereby assigns and agrees to assign, and shall cause its Affiliates to assign and agree to assign, to Miravant all right, title and interest in such Development Technology conceived by employees or consultants of P&U or its Affiliates, either solely or jointly with others.
Sample 1
Development Technology. “Development Technology shall specifically exclude any service utilizing the Licensed Technology or mice claimed in the Mayo Patent Rights, which service is performed on behalf of a third party.”
Sample 1
AutoNDA by SimpleDocs
Development Technology. Notwithstanding Section 6.2.2, as between the Parties, [***].
Sample 1
Development Technology 
Sample 1Sample 2

Related to Development Technology

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

Time is Money Join Law Insider Premium to draft better contracts faster.